Non-Uterine Research Updates-
2021:
The role of 18 F-FDG PET/CT in retroperitoneal sarcomas-A multicenter retrospective study
2020:
Georgios_Kantidakis_Presentation_ESMO2020
Guide Patient election for Resection of Sarcoma Lung metastases
Radiotherapy for Adult Soft Tissue Sarcomas of the Head and Neck
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing
PharmaMar presents results of trabectedin & doxorubicin for first line treatment of leiomyosarcomas at ASCO 2020
Madrid, June 1st, 2020.- PharmaMar (MSE:PHM) has announced that the final results from the Phase II study of trabectedin in combination with doxorubicin for the treatment of patients with advanced metastatic uterine and soft tissue leiomyosarcoma have been presented in an Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting, that was held on May 29th to 31st, 2020.
Under the title “A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study” (Abstract 11506), Patricia Pautier, MD, from the Medical Oncology Department, Institut Gustave Roussy, Villejuif, France, has concluded that trabectedin in combination with doxorubicin is an effective first-line treatment for patients with leiomyosarcoma.
The study achieved its primary and secondary endpoints, with a median Progression-Free Survival (PFS) of 10.1 months; a median Overall Survival (OS) of 34.4 months and an acceptable safety profile.
As a reference (not comparable head-to-head studies), the most recent results of other doxorubicin combinations, such as those presented in ASCO 2019 in the “ANNOUNCE” Phase III study (doxorubicin + olaratumumab), reported a median PFS of 6.9 months, and an OS of 21.9 months (ASCO 2019 LBA3)[1].
Patricia Pautier, MD, said: “Combination of doxorubicin and trabectedin constitutes an active first-line therapy for patients with uterine and soft tissue leiomyosarcoma. Results in overall response rate, progression free survival and now in overall survival are very encouraging.” And added: “Results of the LMS04 trial, a randomized phase-III study comparing this combination followed by trabectedin versus doxorubicin alone in 1st-line therapy in metastatic LMS are pending.”
2019:
BRCA ½ Functional Loss Defines a Targetable Subset in Leiomyosarcoma
https://www.ncbi.nlm.nih.gov/
Dr. Breelyn Wilky at Univ. of Colorado Health Sciences, Denver, CO recently gave a talk on some of the research that being developed in the lab and in clinic on improving outcomes with immunotherapy in sarcomas. It’s long and pretty scientific-focused, but reviews the major immunotherapy trials for sarcomas, and talks about ideas about how to move forward. View the video here.
CT imaging improves histopathological grading of retroperitoneal leiomyosarcomas
of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
2018:
-
- Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib
- Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model
- Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease
- A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma
-
ELSEVIER RESEARCH ARTICLES – UPDATES ON LEIOMYOSARCOMAYou can go to this site directly for information updates on Leiomyosarcoma – There are many articles to see for LMS and ULMS.
- UPDATE FROM THE NATIONAL INSTITUTES OF HEALTH (NIH):
- Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma
- Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity
-
Dr. Lara Davis, OHSU physician, researcher shares her research: Discovery and characterization of novel, recurrent, targetable ALK fusions in leiomyosarcoma
The result of this research provides the first validation of a targetable oncogenic kinase fusion as a driver in a subset of leiomyosarcomas. Overall, these findings suggest that some soft tissue sarcomas may harbor previously unknown kinase gene translocations, and their discovery may propel new therapeutic strategies in this treatment-refractory cancer.
- Discovery and characterization of recurrent, targetable ALK fusions in leiomyosarcoma
- Trabectedin, Doxorubicin, and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
- Cancer research stories from Stanford Medicine and the Stanford Cancer Institute
Read about cancer research from Stanford Medicine’s News & Publications
Twitter updates available @StanfordCancer
- In select sarcoma subtypes, researchers determined the disease control rate (DCR) with sorafenib plus dacarbazine. They examined patients with leiomyosarcoma (LMS), synovial sarcoma (SS), or malignant peripheral nerve sheath tumors (MPNST) with up to two previous lines of therapy and adequate hepatic, renal, and marrow function. Treatment regimen for these subjects comprised 3-week cycles of sorafenib at 400 mg oral twice daily and dacarbazine 1,000 mg/m2 intravenously (later reduced to 850 mg/m2). An 18-week DCR of 46% was documented in this study. Modest clinical activity of dacarbazine + sorafenib was evident in patients with these diagnoses. Dacarbazine + sorafenib was feasible and related to favorable disease-control rates; however, this combination also increased the potential for significant toxicity. Read the full article on The Oncologist
one NTRK fusion and it was very exciting.” – from Dr. Neeta Somaiah, MD, Sarcoma Research, Anderson Cancer Center.
A phase II study of tumor ablation in patients with metastatic sarcoma stable on chemotherapy
A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers
Adjuvant Therapy Does Not Improve Survival for Early Stage Uterine Leiomyosarcoma
Cancer ‘vaccine’ eliminates tumors in mice
Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates
Next-generation sequencing for patients with sarcoma: A single center experience
Nivolumab With Ipilimumab Promising for Pretreated Metastatic Sarcoma
Options for Adjuvant Therapy for Uterine Leiomyosarcoma
Soft Tissue and Uterine Leiomyosarcoma
Leiomyosarcoma Articles by Dr. Alexander Lazar:
Dr. Alexander Lazar (medical advisory council member) is a research pathologist from MD Anderson Cancer Center in Houston, Texas.
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas
Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma
Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas
Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value